Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.53 |
| ▸ | LCK | P06239 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | BRAF | P15056 | 1/20 | 0.52 |
| ▸ | KIT | P10721 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2459361 | 0.96 | MAPT (0.55) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2462967 | 0.89 | MAPT (0.65) | MAPTRXFP1LCKMAPK14KIT | |
| SCHEMBL2461431 | 0.88 | MAPT (0.55) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2459887 | 0.86 | MAPT (0.55) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2457417 | 0.85 | MAPT (0.60) | MAPTRXFP1LCKMAPK14KIT | |
| SCHEMBL2456475 | 0.84 | MAPT (0.55) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2462224 | 0.83 | MAPT (0.52) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2460892 | 0.83 | MAPT (0.60) | MAPTRXFP1LCKMAPK14KIT | |
| SCHEMBL2465864 | 0.82 | MAPT (0.55) | MAPTRXFP1LCKMAPK14KDR | |
| SCHEMBL2459889 | 0.80 | MAPT (0.53) | MAPTRXFP1LCKMAPK14KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044041-B2 | e.g. 4-Chloro-1-hydroxy-phthalazine-6-carboxylic acid [4-chloro-3'-(2-dimethylamino-ethoxy)-biphenyl-3-yl]-amide; multifunctioning protein kinase inhibitors; anticarcinogenic, antiinflammatory, antidiabetic agent, neurodegenerative diseases | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2011-10-25 | — | — | US | disclosed |
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | ARALDI GIAN-LUCA | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237571-A1 | PHTHALAZINE DERIVATIVES | CDK5, HIPK2, PACSIN2 | MAPT 653/4885RXFP1 4802/4885LCK 271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.